Darwin Discovery Limited

Arakis Ltd.

Chiroscience, Ltd.

Hazel Judith Bardsley

Robert William Gristwood

Julian Clive Gilbert

Andrew John Richards

Andrew John McGlashan Richards

Robin Mark Bannister

Laurence E Mather

The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.

Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration

The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.

Corticosteroid formulation

Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is disposed to adverse systemic side-effects, e.g., one who is CNS-compromised or predisposed to CNS side-effects. A unit dose of levobupivacaine comprising at least 75 mg to less than 200 mg of levobupivacaine is described herein.

Levobupivacaine as an analgesic agent

A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (&plus;)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (&minus;)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

Dosage forms

Aqueous pharmaceutical compositions comprising levobupivacaine((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide ), that are particularly useful in a patient who is disposed to adverse systemic side-effects, are disclosed.

Analgesic agent and its use

A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (+)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (-)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

Pharmaceutical drug dosage forms providing different release rates

Levobupivacaine for managing chronic pain

Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is CNS-compromised or predisposed to CNS side-effects. It is also useful as an anesthetic in obstetrics.

Growing community of inventors

Cambridge, United Kingdom

Hazel Judith Bardsley